SB 265610

Key Product Details

Product Description

SB 265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca²⁺ mobilization (IC₅₀ values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.

Licensing Information

Sold for research purposes under agreement from GlaxoSmithKline

Product Specifications for SB 265610

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SB 265610

The following data is based on the product molecular weight 357.16.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

6 5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.80 mL	14.00 mL	28.00 mL
5 mM	0.56 mL	2.80 mL	5.60 mL
10 mM	0.28 mL	1.40 mL	2.80 mL
50 mM	0.06 mL	0.28 mL	0.56 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 24 publications citing the usage of this product.

• Milatovic Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 2003 PMID: 12753603
• Auten Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J.Pharmacol.Exp.Ther. 2001 PMID: 11561067

Product Documents for SB 265610